SCORE2-OP-guided statin initiation for primary prevention in adults aged 70–89 years without diabetes: evidence for age-specific risk thresholds

Clicks: 13
ID: 327620
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #262 of 288 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 288 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims Current guidelines suggest a unique 10-year cardiovascular disease (CVD) risk threshold for the oldest to consider lipid-lowering treatment for CVD prevention. We aimed to assess the benefit of initiating primary prevention with statins in non-diabetic adults aged 70-89 according to their SCORE2-OP, and to explore risk thresholds for different ages. Methods We conducted an observational retrospective cohort study with the Catalan primary care database (SIDIAP) with an intention-to-treat approach. We assessed incident CVD (myocardial infarction and stroke), all-cause mortality, and adverse effects. Overall and age-stratified propensity-adjusted Cox proportional hazard models were fitted, using restricted cubic splines for the treatment interaction with SCORE2-OP. Results We analyzed 167,360 individuals (mean age 77.70 years; 36.9% men). The mean baseline SCORE2-OP risk was 13.81%. Overall, treatment was not associated with a CVD reduction in lower risks, with a protective association becoming stable around a SCORE2-OP of 16% (HR=0.90 [0.84-0.96]). The different age groups reached similar protective associations (HR ≈ 0.85), but at different estimated risks. A mild significant increase of type 2 diabetes was observed in statin initiators (1.07 [1.02-1.12]). We did not observe a protective association with all-cause mortality across the whole estimated risk spectrum. Conclusions Age-specific risk thresholds of the SCORE2-OP estimated risk may be further developed and considered when weighing the benefits of initiating primary prevention of incident CVD with statins in non-diabetic adults aged 70+. Our results do not support treatment initiation of primary prevention to reduce all-cause mortality at any level of estimated CVD risk.
Reference Key
openalex_W7208740899 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lluís Zacarías‐Pons, Jordi Blanch, Lia Alves‐Cabratosa, Gina Domínguez‐Armengol, Ruth Martí‐Lluch, Francesc Ribas‐Aulinas, Anna Ponjoan, Víctor Romero, Luis García‐Ortiz, Isabel del Cura-González, Rafel Ramos
Are you one of these authors? Claim your profile
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag469
URL
https://doi.org/10.1093/eurjpc/zwag469
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.